Oxford BioMedica (LSE:OXB), a leading gene therapy company, and The Foundation Fighting Blindness (FFB) through its translational research arm National Neurovision Research Institute (NNRI) announced today that they have signed a research and collaboration agreement to develop a portfolio of gene therapy products for the treatment of eye diseases. This builds on the existing agreement with FFB signed in November 2003 for the pre-clinical development of RetinoStat®, Oxford BioMedica’s product for the treatment of age-related macular degeneration (AMD) and for which Oxford BioMedica expects to file an IND application in 2007. The first product in the expanded portfolio will be StarGen™ for the treatment of Stargardt disease, the most common juvenile degenerative retinal disease.
